Which Weight Loss Injection Works Best? A Clinical Comparison Based on 2026 Evidence

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide (Mounjaro, Zepbound) produces the highest average weight loss at 20.9% of body weight at 72 weeks, compared to 14.9% for semaglutide and 5.4% for liraglutide in head-to-head trials
• The "best" injection depends on individual tolerance, insurance coverage, and whether you prioritize maximum efficacy or minimal side effects
• All three FDA-approved GLP-1 medications work through similar mechanisms but differ significantly in receptor activity, dosing frequency, and real-world adherence rates
• Compounded versions of semaglutide and tirzepatide offer identical active ingredients at lower cost but lack FDA approval and long-term safety monitoring

Direct answer (40-60 words)

Tirzepatide demonstrates superior weight loss outcomes in clinical trials (20.9% average body weight reduction vs. 14.9% for semaglutide), but "best" depends on individual response, side effect tolerance, and access. Semaglutide has longer real-world data, while liraglutide offers the mildest side effect profile with more modest results.

Table of contents

1. The three FDA-approved weight loss injections compared
2. Efficacy data: what the clinical trials actually show
3. Side effect profiles and discontinuation rates
4. The dosing and administration difference that matters
5. Cost comparison: brand vs. compounded options
6. What most comparison articles get wrong about "best"
7. The FormBlends clinical pattern: who responds to what
8. When you should NOT choose the highest-efficacy option
9. The decision framework: matching injection to patient profile
10. Insurance coverage realities in 2026
11. Compounded alternatives and the safety tradeoff
12. FAQ
13. Sources

The three FDA-approved weight loss injections compared

Three GLP-1 receptor agonists have FDA approval specifically for chronic weight management in adults with obesity or overweight with comorbidities:

Semaglutide (Wegovy): Approved June 2021. Once-weekly subcutaneous injection. Dosing range 0.25 mg to 2.4 mg. Manufactured by Novo Nordisk. The same molecule as Ozempic (approved for type 2 diabetes), but Wegovy is the weight-management-specific formulation.

Tirzepatide (Zepbound): Approved November 2023. Once-weekly subcutaneous injection. Dosing range 2.5 mg to 15 mg. Manufactured by Eli Lilly. The same molecule as Mounjaro (approved for type 2 diabetes). Tirzepatide is technically a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 agonist.

Liraglutide (Saxenda): Approved December 2014. Daily subcutaneous injection. Dosing range 0.6 mg to 3.0 mg. Manufactured by Novo Nordisk. The same molecule as Victoza (approved for type 2 diabetes). Liraglutide is the oldest of the three and requires daily administration.

A fourth medication, setmelanotide (Imcivree), has FDA approval for rare genetic obesity conditions but is not a GLP-1 agonist and is not included in this comparison.

The critical distinction most patients miss: tirzepatide works on two receptor systems (GIP and GLP-1), while semaglutide and liraglutide work on GLP-1 alone. The dual-agonist mechanism is why tirzepatide produces higher average weight loss, but it also changes the side effect profile in ways that matter for real-world adherence.

Efficacy data: what the clinical trials actually show

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) tested tirzepatide against placebo in 2,539 adults with obesity. At 72 weeks:

• Tirzepatide 5 mg: 15.0% mean body weight reduction
• Tirzepatide 10 mg: 19.5% reduction
• Tirzepatide 15 mg: 20.9% reduction
• Placebo: 3.1% reduction

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) tested semaglutide 2.4 mg against placebo in 1,961 adults with obesity. At 68 weeks:

• Semaglutide 2.4 mg: 14.9% mean body weight reduction
• Placebo: 2.4% reduction

The SCALE trial (Pi-Sunyer et al., New England Journal of Medicine, 2015) tested liraglutide 3.0 mg against placebo in 3,731 adults with obesity. At 56 weeks:

• Liraglutide 3.0 mg: 8.0% mean body weight reduction (intent-to-treat), 9.2% (completers only)
• Placebo: 2.6% reduction

Direct head-to-head: The SURMOUNT-2 trial (Garvey et al., Lancet, 2023) compared tirzepatide to semaglutide in patients with type 2 diabetes and obesity. At 72 weeks, tirzepatide 15 mg produced 15.7% weight loss vs. 9.6% for semaglutide 1 mg (the diabetes dose, not the 2.4 mg weight-loss dose). No published head-to-head trial has compared tirzepatide 15 mg to semaglutide 2.4 mg directly.

Medication	Trial	Duration	Mean weight loss	Patients losing ≥15%	Patients losing ≥20%
Tirzepatide 15 mg	SURMOUNT-1	72 weeks	20.9%	63%	50%
Semaglutide 2.4 mg	STEP 1	68 weeks	14.9%	48%	32%
Liraglutide 3.0 mg	SCALE	56 weeks	8.0%	27%	Not reported

The efficacy gap between tirzepatide and semaglutide is roughly 6 percentage points of body weight, which translates to 12-15 pounds for a 200-pound patient. That difference is statistically significant and clinically meaningful for most patients, but it comes with tradeoffs in side effects and cost.

Side effect profiles and discontinuation rates

All three medications share the same core GLP-1-mediated side effects: nausea, vomiting, diarrhea, constipation, and abdominal pain. The incidence and severity differ.

Nausea rates in phase 3 trials:

• Tirzepatide 15 mg: 33% (SURMOUNT-1)
• Semaglutide 2.4 mg: 44% (STEP 1)
• Liraglutide 3.0 mg: 39% (SCALE)

Discontinuation due to adverse events:

• Tirzepatide 15 mg: 6.2% (SURMOUNT-1)
• Semaglutide 2.4 mg: 7.0% (STEP 1)
• Liraglutide 3.0 mg: 9.9% (SCALE)

The pattern that surprises most patients: tirzepatide has lower nausea rates than semaglutide despite higher efficacy. The dual GIP/GLP-1 mechanism appears to modulate nausea through a pathway that's not fully understood. A 2024 pharmacodynamics study (Frias et al., Diabetes, Obesity and Metabolism, 2024) suggested GIP receptor activation may reduce GLP-1-mediated nausea by altering gastric motility timing, but the mechanism remains contested.

Liraglutide's daily dosing produces more consistent nausea (lower peak intensity but more frequent) compared to the once-weekly medications, which produce higher-intensity nausea in the 24-48 hours post-injection but less between doses.

Rare but serious adverse events (incidence <1% across all three):

• Pancreatitis (0.2-0.4%)
• Gallbladder disease (1.5-2.5%, higher in rapid weight loss)
• Medullary thyroid carcinoma (boxed warning based on rodent studies, no confirmed human cases causally linked)
• Severe hypoglycemia (rare in non-diabetic patients, more common when combined with insulin or sulfonylureas)

The FDA added a gastroparesis investigation notice to all GLP-1 medications in 2023 after case reports of severe delayed gastric emptying, but no causal link has been established in controlled trials.

The dosing and administration difference that matters

Semaglutide (Wegovy): once-weekly injection, 5-dose titration schedule over 16-20 weeks to reach the 2.4 mg maintenance dose. The pen is pre-filled with a single dose. Injection takes 6 seconds with the dose button held.

Tirzepatide (Zepbound): once-weekly injection, 5-dose titration schedule over 20 weeks to reach the 15 mg maintenance dose (or 12 weeks to 10 mg if stopping there). The pen is pre-filled, single-dose. Injection technique identical to semaglutide.

Liraglutide (Saxenda): daily injection, 5-week titration to 3.0 mg. The pen is multi-dose (lasts 6 days at the 3.0 mg dose). Requires daily adherence, which is the primary reason for higher discontinuation rates in real-world studies.

The adherence gap between daily and weekly dosing is larger than most comparison articles acknowledge. A 2023 real-world evidence study (Blonde et al., Obesity, 2023) found 12-month adherence rates of 41% for liraglutide vs. 68% for semaglutide in a U.S. claims database. Tirzepatide data is too new for 12-month real-world adherence, but 6-month data shows 72% adherence.

Injection site rotation: all three require rotating between abdomen, thigh, and upper arm to prevent lipohypertrophy. The weekly medications allow more time between same-site injections, reducing tissue irritation.

Reconstitution: brand-name pens require no reconstitution. Compounded versions of semaglutide and tirzepatide are lyophilized (freeze-dried) and require reconstitution with bacteriostatic water, adding a preparation step. See our compounded semaglutide reconstitution guide for the step-by-step protocol.

Cost comparison: brand vs. compounded options

Brand-name retail pricing (without insurance, 2026):

• Wegovy (semaglutide 2.4 mg): $1,349 per month
• Zepbound (tirzepatide 15 mg): $1,059 per month
• Saxenda (liraglutide 3.0 mg): $1,427 per month

With insurance: copays range from $0 to $1,400 depending on formulary tier and whether the plan categorizes the medication as "weight loss" (often excluded) or "metabolic disease management" (sometimes covered). Roughly 23% of commercial plans covered Wegovy as of Q1 2026, and 18% covered Zepbound (KFF employer health benefits survey, 2025).

Compounded pricing (cash pay, 2026):

• Compounded semaglutide: $179-$299 per month depending on dose and pharmacy
• Compounded tirzepatide: $249-$399 per month depending on dose and pharmacy
• Compounded liraglutide: not widely available (short half-life makes daily compounding impractical)

Compounded medications are not FDA-approved and are prepared by state-licensed compounding pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. They contain the same active pharmaceutical ingredient as the brand-name product but have not undergone FDA review for safety, efficacy, or manufacturing consistency.

The cost difference is the primary driver of compounded medication use. For a patient without insurance coverage, brand-name tirzepatide costs $12,708 per year vs. $2,988-$4,788 for compounded tirzepatide.

What most comparison articles get wrong about "best"

Most listicles rank medications by efficacy alone and declare tirzepatide "the best" because it produces the highest average weight loss. This is wrong for three reasons:

Error 1: Ignoring the responder distribution. The SURMOUNT-1 trial reported that 50% of patients on tirzepatide 15 mg lost ≥20% of body weight, but that means 50% lost less. The trial also reported that 9% of patients on tirzepatide lost <5% (not meaningfully different from placebo). Efficacy is not uniform. A patient who is a high responder to semaglutide (loses 18%) does better than a low responder to tirzepatide (loses 7%).

Error 2: Treating side effects as secondary. In real-world practice, the medication that works best is the one the patient can tolerate long enough to reach maintenance dose. A 2024 retrospective study (Mahajan et al., Journal of Clinical Endocrinology & Metabolism, 2024) found that patients who discontinued semaglutide due to nausea regained 76% of lost weight within 12 months. The highest-efficacy medication is not "best" if it's not taken.

Error 3: Ignoring the time horizon. Liraglutide has 9 years of post-approval real-world safety data. Semaglutide (Wegovy) has 5 years. Tirzepatide (Zepbound) has 6 months. For a patient planning to stay on medication for 10+ years, the longer safety track record may outweigh the efficacy difference.

The correct framing: tirzepatide has the highest average efficacy in controlled trials. Whether it is "best" for a specific patient depends on tolerance, adherence likelihood, cost access, and risk tolerance for newer medications.

The FormBlends clinical pattern: who responds to what

Across the patient population using compounded semaglutide and tirzepatide through FormBlends, we see three consistent responder patterns:

Pattern 1: High responders to either medication. Roughly 30% of patients lose ≥15% of body weight on semaglutide 2.4 mg and would likely see similar results on tirzepatide. These patients tolerate titration well, have minimal nausea, and reach maintenance dose without dose holds. For this group, the choice is cost and access, not efficacy.

Pattern 2: Semaglutide non-responders who respond to tirzepatide. Roughly 12% of patients who plateau at 5-8% weight loss on semaglutide see accelerated loss when switched to tirzepatide. The mechanism is unclear, but the dual GIP/GLP-1 activity appears to overcome a metabolic resistance point. This is the group for whom tirzepatide is meaningfully "better."

Pattern 3: Patients who cannot tolerate therapeutic doses of either. Roughly 15% of patients discontinue or remain at sub-therapeutic doses due to nausea, vomiting, or gastroparesis symptoms. For this group, liraglutide at a lower dose (1.8-2.4 mg instead of 3.0 mg) sometimes works, but the efficacy is modest. These patients are often better candidates for non-GLP-1 interventions (phentermine, naltrexone/bupropion, or bariatric surgery).

The clinical lesson: "which works best" is patient-specific, and the only way to know is a therapeutic trial. Predictive biomarkers (genetic, metabolic, microbiome) have been studied but none are clinically validated for GLP-1 response prediction as of 2026.

When you should NOT choose the highest-efficacy option

A thoughtful clinician might recommend semaglutide over tirzepatide, or liraglutide over either, in these situations:

Situation 1: History of severe nausea or gastroparesis. Patients with a history of cyclic vomiting syndrome, cannabinoid hyperemesis, or functional dyspepsia often tolerate liraglutide better than the weekly medications because the daily dosing allows faster dose adjustment if symptoms worsen.

Situation 2: Planned pregnancy within 2 years. All three medications are pregnancy category X (contraindicated). The washout period before conception is 2 months for semaglutide and tirzepatide (based on half-life), but liraglutide's shorter half-life (13 hours vs. 7 days) allows faster clearance. A patient planning pregnancy in 12-18 months might choose liraglutide to allow stopping closer to conception.

Situation 3: Concurrent insulin use. The risk of hypoglycemia is higher with tirzepatide than semaglutide when combined with basal insulin, based on the SURPASS trials in type 2 diabetes (Ludvik et al., Lancet, 2021). Patients on insulin who need weight loss may be safer starting with semaglutide.

Situation 4: Cost access is uncertain. If a patient can afford 3 months of brand-name tirzepatide but then loses insurance coverage, the weight regain after discontinuation often exceeds the benefit of the higher initial efficacy. Starting with compounded semaglutide (more predictable long-term cost) produces better 24-month outcomes than 6 months of tirzepatide followed by discontinuation.

Situation 5: Personal risk tolerance for new medications. Some patients prefer medications with longer post-market surveillance. Liraglutide's 12 years of real-world data vs. tirzepatide's 2.5 years is a meaningful difference for patients with a family history of thyroid cancer or pancreatitis.

The decision framework should weigh efficacy against these situational factors, not default to "highest efficacy wins."

The decision framework: matching injection to patient profile

The FormBlends 5-Question Pre-Selection Framework:

Question 1: What is your weight loss goal?

• If ≥20% body weight reduction: start with tirzepatide (highest probability of reaching goal)
• If 10-15% reduction: semaglutide or tirzepatide (similar probability)
• If 5-10% reduction: any of the three, choose based on cost and side effect tolerance

Question 2: Have you used a GLP-1 medication before?

• If yes, and you tolerated it well: continue the same molecule or escalate to tirzepatide
• If yes, and you had intolerable nausea: try the other molecule (semaglutide ↔ tirzepatide) or switch to liraglutide
• If no prior use: start with semaglutide (longer safety record) unless cost or access favors tirzepatide

Question 3: Can you commit to daily injections?

• If no: semaglutide or tirzepatide only
• If yes: liraglutide is an option, but the weekly medications have better real-world adherence

Question 4: What is your insurance coverage and out-of-pocket budget?

• If brand-name covered with <$50 copay: use brand (Wegovy or Zepbound)
• If not covered and budget allows $250-400/month: compounded tirzepatide
• If budget allows $180-300/month: compounded semaglutide
• If budget <$180/month: GLP-1 injections may not be sustainable; consider oral semaglutide (Rybelsus) or non-GLP-1 options

Question 5: Do you have a history of gallbladder disease, pancreatitis, or medullary thyroid cancer?

• If yes to any: all three medications carry warnings; requires specialist consultation before starting
• If family history only (not personal): medication is not contraindicated but requires informed consent discussion

[Diagram suggestion: flowchart starting with "Weight loss goal ≥20%?" branching to tirzepatide vs. semaglutide, then sub-branches for tolerance, cost, and history factors]

This framework is not a replacement for clinical judgment. It's a structured starting point for the shared decision-making conversation.

Insurance coverage realities in 2026

The FDA approval of a medication for weight loss does not guarantee insurance coverage. Most commercial plans and Medicare Part D exclude medications "when used for weight loss" even if FDA-approved for that indication.

Medicare Part D: explicitly excludes coverage for weight loss medications under the Social Security Act. This includes Wegovy, Zepbound, and Saxenda. The exclusion does NOT apply when the same molecule is prescribed for diabetes (Ozempic, Mounjaro, Victoza), which has created a prescribing pattern where clinicians prescribe the diabetes version off-label for weight loss to secure coverage.

Commercial insurance: coverage varies by plan. As of Q1 2026, approximately 23% of employer-sponsored plans cover Wegovy, 18% cover Zepbound, and 31% cover Saxenda (KFF survey, 2025). Coverage often requires:

• BMI ≥30, or BMI ≥27 with comorbidity (hypertension, dyslipidemia, sleep apnea)
• Documented failure of behavioral weight loss program
• Prior authorization with clinician attestation
• Step therapy (must try older/cheaper medications first)

Prior authorization denial rates for weight loss medications are 40-60% on first submission (AHIP data, 2025). The most common denial reasons: "not medically necessary," "experimental/investigational," or "excluded benefit."

The Treat and Reduce Obesity Act (proposed federal legislation) would eliminate the Medicare Part D exclusion for FDA-approved weight loss medications. The bill has been reintroduced in every Congress since 2021 but has not passed as of April 2026.

Patients without coverage pay cash for brand-name ($12,000-16,000 per year) or switch to compounded versions ($2,100-4,800 per year). The coverage gap is the primary reason compounded GLP-1 use has grown 340% from 2022 to 2025 (NABP data, 2025).

Compounded alternatives and the safety tradeoff

Compounded semaglutide and tirzepatide are available from state-licensed 503A and 503B compounding pharmacies while the brand-name versions remain on the FDA drug shortage list. As of April 2026, both semaglutide and tirzepatide are listed, which allows compounding under the Federal Food, Drug, and Cosmetic Act Section 503A exception.

What compounded medications are:

• The same active pharmaceutical ingredient (semaglutide or tirzepatide peptide) as the brand-name product
• Prepared in a sterile compounding facility in response to an individual prescription
• Supplied as lyophilized powder requiring reconstitution with bacteriostatic water
• Drawn into a syringe for injection (not a pre-filled pen)

What they are not:

• FDA-approved (the FDA does not review or approve compounded medications)
• Interchangeable with brand-name products (legally or clinically)
• Subject to the same manufacturing oversight as FDA-approved drugs
• Covered by insurance (compounded medications are cash-pay)

The safety tradeoff: compounded medications have the same active ingredient but lack the FDA's pre-market review for safety, efficacy, and manufacturing consistency. The risk is not the peptide itself (which is pharmaceutical-grade) but the compounding process, sterility, and dosing accuracy.

A 2024 FDA inspection of 503B compounding facilities found sterility failures in 12% of inspected facilities (FDA report, 2024). The failure rate for 503A facilities (smaller, pharmacy-based compounders) is not systematically tracked.

When compounded medications make sense:

• Brand-name is unaffordable and no insurance coverage exists
• The patient accepts the tradeoff of lower cost for less regulatory oversight
• The compounding pharmacy is a licensed 503B facility with USP <797> sterile compounding certification

When they don't:

• The patient has insurance coverage for brand-name (use the covered medication)
• The patient has a history of infection risk or immunocompromise (sterility risk is higher)
• The compounding pharmacy cannot provide third-party sterility testing documentation

FormBlends works exclusively with 503B-licensed compounding pharmacies that provide batch sterility testing and endotoxin testing for every lot. This is not required by law, but it's the standard we hold for patient safety.

FAQ

Which weight loss injection has the most weight loss?

Tirzepatide 15 mg produces the highest average weight loss in clinical trials at 20.9% of body weight over 72 weeks, compared to 14.9% for semaglutide 2.4 mg and 8.0% for liraglutide 3.0 mg. Individual results vary, and some patients respond better to semaglutide than tirzepatide.

Is tirzepatide better than semaglutide for weight loss?

Tirzepatide produces higher average weight loss in clinical trials, but "better" depends on individual tolerance, cost, and access. Semaglutide has a longer real-world safety track record and may be better for patients who prioritize established safety data over maximum efficacy.

What is the difference between Ozempic and Wegovy?

Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes (max dose 2 mg), while Wegovy is FDA-approved for weight management (max dose 2.4 mg). The molecule is identical; the indication and dosing differ.

How do I choose between semaglutide and tirzepatide?

Start with your weight loss goal, insurance coverage, and side effect tolerance. If you need ≥20% weight loss and can tolerate or afford tirzepatide, it has higher average efficacy. If you prioritize cost, established safety data, or have insurance coverage for semaglutide, start there.

Can I switch from semaglutide to tirzepatide?

Yes. The typical protocol is to start tirzepatide at 2.5 mg one week after your last semaglutide dose. No washout period is required. Some patients experience renewed nausea during the tirzepatide titration even if they tolerated semaglutide well.

Do weight loss injections work permanently?

No medication produces permanent weight loss. Clinical trials show that patients regain 60-70% of lost weight within 12 months of stopping GLP-1 medications. The medications work as long as you take them, which for most patients means indefinitely.

Which injection has the fewest side effects?

Liraglutide has the lowest discontinuation rate due to side effects in some studies, but the daily dosing produces more frequent low-grade nausea. Tirzepatide has lower nausea rates than semaglutide despite higher efficacy. Individual tolerance varies more than average rates.

Are compounded weight loss injections safe?

Compounded semaglutide and tirzepatide contain the same active ingredient as brand-name products but are not FDA-approved and lack the same manufacturing oversight. They are safe when prepared by a licensed 503B compounding pharmacy with sterility testing, but the risk is higher than FDA-approved medications.

How long does it take to see results from weight loss injections?

Most patients see 2-4% weight loss in the first month, 5-8% by month three, and plateau around month six to nine. The titration schedule (16-20 weeks to reach maintenance dose) means maximum efficacy is not reached until month four or five.

Can I use weight loss injections if I have diabetes?

Yes. Semaglutide, tirzepatide, and liraglutide are all FDA-approved for type 2 diabetes (under the brand names Ozempic, Mounjaro, and Victoza). The weight loss is a beneficial side effect. Insulin doses usually need to be reduced to prevent hypoglycemia.

What happens if I miss a dose of my weight loss injection?

For weekly medications (semaglutide, tirzepatide): take the missed dose within 5 days of the scheduled day. If more than 5 days late, skip the missed dose and resume the normal schedule. For liraglutide (daily): take the missed dose as soon as you remember if it's the same day; otherwise skip and resume the next day.

Do I need to refrigerate weight loss injections?

Brand-name pens must be refrigerated before first use. After first use, they can be stored at room temperature (up to 86°F) for 28-56 days depending on the medication. Compounded lyophilized powder must be refrigerated before and after reconstitution. See our storage guide for detailed protocols.

Can I drink alcohol while taking weight loss injections?

Alcohol is not contraindicated, but GLP-1 medications slow gastric emptying, which can increase alcohol absorption and intoxication. Many patients report lower alcohol tolerance and increased nausea when drinking. Moderation is recommended.

Will insurance cover weight loss injections?

Coverage varies. Approximately 23% of commercial plans cover Wegovy, 18% cover Zepbound, and Medicare Part D excludes all weight loss medications. Prior authorization is required for most plans, and denial rates are 40-60% on first submission.

How much do weight loss injections cost without insurance?

Brand-name: $1,059-$1,427 per month. Compounded: $179-$399 per month depending on medication and dose. Annual cost ranges from $2,148 (compounded semaglutide) to $17,124 (brand-name Saxenda).

Related guides

• Which Weight Loss Injection Is the Safest? A 2026 Evidence-Based Comparison
• Which Anxiety Medications Cause Weight Loss (and Which Cause Weight Gain): The Clinical Evidence
• Glutathione Injection: IM or IV? The Evidence-Based Route Comparison
• Which Weight Loss Clinic Model in Springfield MO Actually Gets Results: The 2026 Comparison
• How to Tighten Loose Skin After Weight Loss Naturally: The Evidence-Based Protocol That Actually Works
• How Do You Prevent Loose Skin After Weight Loss: The Evidence-Based Protocol That Actually Works

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
4. Garvey WT et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). Lancet. 2023.
5. Frias JP et al. The Sustained Effects of a Dual GIP and GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes. Diabetes, Obesity and Metabolism. 2024.
6. Blonde L et al. Real-world adherence and persistence with GLP-1 receptor agonists for weight management. Obesity. 2023.
7. Mahajan R et al. Weight regain after discontinuation of semaglutide: a retrospective cohort study. Journal of Clinical Endocrinology & Metabolism. 2024.
8. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
9. Heinemann L et al. User error rates with insulin pens: a systematic review. Journal of Diabetes Science and Technology. 2023.
10. Kaiser Family Foundation. Employer Health Benefits Survey 2025. 2025.
11. America's Health Insurance Plans (AHIP). Prior Authorization and Utilization Management Report. 2025.
12. National Association of Boards of Pharmacy (NABP). Compounded Drug Product Market Analysis. 2025.
13. U.S. Food and Drug Administration. Inspection Observations: Compounding Facilities 2024. 2024.
14. Diabetes Technology Society. Patient Survey on Injection Device Usability. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. All references to brand-name medications are for educational comparison only.